A hybridoma-derived CX3CR1-targeting monoclonal antibody strategy was presented as an oral presentation, highlighting neuroimmune pain modulation in pancreatic disease.
Our CX3CR1 antibody development programme was presented as an oral presentation at an international immunology stage.
The work focuses on the fractalkine–CX3CR1 axis, a neuroimmune signalling pathway implicated in pancreatic disease-associated pain, inflammation and tissue remodelling. The programme progressed from target rationale and immunisation strategy to hybridoma-based monoclonal antibody generation, screening and preclinical evaluation.
This work reflects one of Imperion’s core translational directions: moving from biological mechanism to antibody development and preclinical validation in disease-relevant models.